{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:45:17Z","timestamp":1762505117434},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,2,8]],"date-time":"2006-02-08T00:00:00Z","timestamp":1139356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>We studied the use of botulinum\u2010a toxin (BTX\u2010A) injections into the bladder as an alternative approach in patients with neurogenic detrusor overactivity due to multiple sclerosis (MS) with drug\u2010refractory overactive bladder (OAB) symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sixteen MS patients\u201411 women, 5 men; mean age 48.6 years\u2014with refractory OAB symptoms were included in a one\u2010center prospective study. For outcome analysis, we used a bladder diary, a complete urodynamic study, and validated questionnaires for subjective assessment. We injected 300 U of BTX\u2010A (Botox\u00ae) into the bladder and into the external sphincter muscle to reduce the probability of posttreatment urine retention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was an increase in residual volume from 81.3\u2009\u00b1\u200923.8 to 126.3\u2009\u00b1\u200932.9 ml after 4 weeks. In one woman, transient self\u2010catheterization was unavoidable. Four weeks and 3 and 6 months after BTX\u2010A injection, the significant results were as follows: daytime frequency was reduced by 29%, 44%, and 30%, respectively. Nocturia diminished by 33%, 72%, and 40%. Use of pads was be reduced by 38% after 4 weeks and by 64% after 3 months. Urodynamically, reflex volume and maximal cystometric bladder capacity increased by 73%, 77%, and 58% (at 6 months, the increase was not significant) and by 36%, 27%, and 36% (not significant). Maximal detrusor pressure decreased by 35%, 22%, and 57%. Subjective outcome indicated significant improvement of symptoms at 4 weeks and 3 months, but not at 6 months. Patient satisfaction with the therapy was very high.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>BTX\u2010A detrusor injections are very effective in the treatment of drug\u2010resistant OAB symptoms in MS patients as reflected in urodynamic measurements and in patient satisfaction. Build up of residual urine remains a problem of which patients must be informed. Neurourol. Urodynam. \u00a9 2006 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.20153","type":"journal-article","created":{"date-parts":[[2006,2,9]],"date-time":"2006-02-09T19:50:34Z","timestamp":1139514634000},"page":"110-115","source":"Crossref","is-referenced-by-count":73,"title":["Efficacy of botulinum\u2010A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: An objective and subjective analysis"],"prefix":"10.1002","volume":"25","author":[{"given":"H.","family":"Schulte\u2010Baukloh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Schobert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Stolze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"St\u00fcrzebecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Wei\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.H.","family":"Knispel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,2,8]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20088"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.56.3.245"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6777(1996)15:6<630::AID-NAU4>3.0.CO;2-G"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1041371"},{"key":"e_1_2_1_7_1","first-page":"351","article-title":"Successful use of bladder botulinum toxin injection to treat refractory overactive bladder","volume":"169","author":"Chancellor M","year":"2003","journal-title":"J Urol"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00552-X"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)01070-0"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)63820-5"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)42717-0"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-9993(03)00202-8"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)53037-2"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(1997)6 <129::AID-MUS9>3.0.CO;2-B"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000117359"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000091281.50081.f0"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2003.12.007"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)61760-9"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5445.1265"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)67524-4"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.01.041"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2003.12.004"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(03)00136-2"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67283-7"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)62695-8"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.1930140206"},{"key":"e_1_2_1_27_1","first-page":"958p","volume-title":"Campbell's urology","author":"Wein AJ","year":"1998"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.20153","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.20153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T02:45:32Z","timestamp":1700534732000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.20153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,8]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1002\/nau.20153"],"URL":"https:\/\/doi.org\/10.1002\/nau.20153","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,8]]}}}